Rock Springs Capital Management LP Nkarta, Inc. Transaction History

Rock Springs Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.19 - $5.17 $135,381 - $319,599	-61,818 Reduced 15.71%	331,571 $726,000
Q4 2022 Feb 14, 2023	SELL	$5.14 - $14.35 $1.15 Million - $3.2 Million	-222,888 Reduced 36.17%	393,389 $2.36 Million
Q2 2022 Aug 15, 2022	BUY	$7.77 - $19.44 $826,176 - $2.07 Million	106,329 Added 20.85%	616,277 $7.59 Million
Q1 2022 May 16, 2022	BUY	$8.66 - $14.99 $23,382 - $40,473	2,700 Added 0.53%	509,948 $5.8 Million
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $52,439 - $110,208	4,100 Added 0.81%	507,248 $7.79 Million
Q3 2021 Nov 15, 2021	BUY	$26.67 - $38.76 $138,684 - $201,552	5,200 Added 1.04%	503,148 $14 Million
Q2 2021 Aug 16, 2021	BUY	$23.94 - $36.68 $146,034 - $223,748	6,100 Added 1.24%	497,948 $15.8 Million
Q1 2021 May 17, 2021	SELL	$31.33 - $59.61 $1.54 Million - $2.93 Million	-49,152 Reduced 9.09%	491,848 $16.2 Million
Q4 2020 Feb 16, 2021	BUY	$27.03 - $75.62 $3,432 - $9,603	127 Added 0.02%	541,000 $33.3 Million
Q3 2020 Nov 16, 2020	BUY	$23.52 - $47.9 $12.7 Million - $25.9 Million	540,873 New	540,873 $16.3 Million

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.